Citations

Citations to this article as recorded by  

• What is the future beyond examining the pathogenicity of the causative organisms in severe infections?: antibody therapy
  Toru Hifumi
  Journal of the Japanese Society of Intensive Care Medicine.2023; 30(4): 223.     CrossRef
• Spontaneous Non-Traumatic Clostridium perfringens Sepsis
  Toru Hifumi
  Japanese Journal of Infectious Diseases.2020; 73(3): 177.     CrossRef
• Severe sepsis caused by a gas-forming Clostridium perfringens and Klebsiella variicola liver abscess following total pancreatectomy
  Stig Søgaard Dahl, Morten Thorsteinsson, Trine-Lise Lambine, Luit Penninga
  BMJ Case Reports.2020; 13(10): e238896.     CrossRef
• Combined therapy with gas gangrene antitoxin and recombinant human soluble thrombomodulin for Clostridium perfringens sepsis in a rat model
  Toru Hifumi, Daisuke Nakano, Joe Chiba, Motohide Takahashi, Akihiko Yamamoto, Yoshihide Fujisawa, Kenya Kawakita, Yasuhiro Kuroda, Akira Nishiyama
  Toxicon.2018; 141: 112.     CrossRef
• Clinical serum therapy
  Toru Hifumi
  Journal of the Japanese Society of Intensive Care Medicine.2018; 25(4): 235.     CrossRef
• Clinical Serum Therapy: Benefits, Cautions, and Potential Applications
  Toru Hifumi, Akihiko Yamamoto, Manabu Ato, Kyoko Sawabe, Kazunori Morokuma, Nobuya Morine, Yutaka Kondo, Eiichiro Noda, Atsushi Sakai, Jin Takahashi, Kazuo Umezawa
  The Keio Journal of Medicine.2017; 66(4): 57.     CrossRef